Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01238666 · ClinicalTrials.gov registry record

Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures

A clinical trial of Liver Cancer, sponsored by Pathfinder Therapeutics.

Completed
Registry status
27
Enrollment target
1
Study location

NCT01238666: Completed study of Liver Cancer, sponsored by Pathfinder Therapeutics.

NCT01238666 is a study of Liver Cancer that has completed, run by Pathfinder Therapeutics. The registered enrollment target is 27 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01238666, a study of Liver Cancer, has completed, sponsored by Pathfinder Therapeutics.

COMPLETED
Registry status
27 participants
Enrollment target
1
Study location

Study Summary

This study was designed in two phases: Phase I is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver ablation procedure and acquires a level of comfort with the procedure. The surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. After registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system three dimensional (3D) image. The surgeon will accept or reject the registration accuracy. The hypothesis is that the surgeon will be able to successfully acquire liver surface registrations with a small learning curve for technique and will be able to proceed to Phase II of the study. Phase II contains the registration process included above but adds the additional process of tracking the ablation probe used to perform tumor ablation by attaching the Pathfinder Multi-Tool adaptor and collecting data showing the location of the ablation probe as tracked and displayed on the Pathfinder three dimensional (3D) image. The surgeon will use ultrasound (US) guidance to locate tumor location during the laparoscopic procedure. The images collected during this process will be recorded by Pathfinder.

Primary Outcome

Subjects are followed for the study 30days (+/- 14 days) and are considered to have completed the study following this 30 day follow-up visit. The performance of accurate physical-to-image registrations obtained during laparoscopic procedures will be evaluated and accepted by the surgeon during the procedure.

Conditions Studied

Study Locations (1)

Oregon

  • Providence Portland Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2010-11
Est. Completion 2012-03
Pathfinder Therapeutics

5 total trials

What the finished NCT01238666 record still lists

NCT01238666 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01238666 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT01238666 about?

NCT01238666 is a clinical study titled "Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures". This study was designed in two phases: Phase I is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver ablation procedure and acquires a level of comfort with the procedur...

What is the current status of trial NCT01238666?

This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-11. Estimated completion is 2012-03.

What conditions does trial NCT01238666 study?

This clinical trial studies the following conditions: Liver Cancer.

Who is sponsoring clinical trial NCT01238666?

This trial is sponsored by Pathfinder Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01238666 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01238666's enrollment target sits among peer trials

27 51st of 78 higher than 28 of 78 other Liver Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01238666, the US trial registry maintained by the National Library of Medicine. NCT01238666 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.